![logo](/logos/ITCI.webp)
Intra-Cellular Therapies, Inc.
NASDAQ:ITCI
73.54 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Intra-Cellular Therapies, Inc. |
Symbool | ITCI |
Munteenheid | USD |
Prijs | 73.54 |
Beurswaarde | 7,770,751,180 |
Dividendpercentage | 0% |
52-weken bereik | 45.5 - 84.89 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. Sharon Mates Ph.D. |
Website | https://www.intracellulartherapies.com |
An error occurred while fetching data.
Over Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)